a7014m
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
01 May
2024 - “Haleon 2024 Q1 Trading Statement”
|
|
99.2
|
|
99.1
Haleon plc: 2024 Q1 Trading Statement
1 May 2024: Haleon
plc's Q1 trading update for the year ended 31 December 2024 is
available at: http://www.rns-pdf.londonstockexchange.com/rns/7006M_1-2024-4-30.pdf.
The Q1 trading statement will also be available on the Haleon
website www.haleon.com/investors,
and the statement has been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders:
A short presentation followed by Q&A will be hosted by Tobias
Hestler, Chief Financial Officer and Sonya Ghobrial, Head of
Investor Relations at 9:00am BST (10:00am CEST) on 1 May 2024,
which can be accessed at www.haleon.com/investors.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 800 279 3956
|
|
US:
|
+1 866 291 4166
|
|
All other:
|
+44 (0) 207 107 0613
|
|
Passcode:
|
43700369
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
|
Enquiries
|
|
|
|
|
|
Investors
|
Media
|
|
Sonya Ghobrial
|
+44 7392 784784
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Nidaa Lone
|
+44 7841 400607
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
May 01, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
エドガーで原本を確認する